TOP STORIES

• BUSINESS Sandoz Gets Approval for Diovan Generics; AGs Likely to Hit Market 6 Months before Rivals
  August 16, 2013

• ACADEMIA British Journal The Lancet Begins Process of Retracting JIKEI Heart Study
  August 16, 2013

• REGULATORY 3 Ex-Officials of MHLW, NHO Affiliated with Novartis in 2010, Govt Says
  August 15, 2013

• REGULATORY PAFSC 2nd Committee to Review GSK’s Combination Asthma Drug on Aug. 26
  August 14, 2013

• REGULATORY EAD Director Visits 5 Hospital HQ to Urge Early Price Settlements, Greeted with Mixed Enthusiasm
  August 13, 2013

• REGULATORY 41,254 ADR Reports Received from Marketing Authorization Holders in FY2012: MHLW
  August 13, 2013

• BUSINESS Payments to Healthcare Professionals by 10 Drug Makers Top 150 Billion Yen
  August 13, 2013

• REGULATORY MHLW Diovan Committee: 3 More Universities Give 1st Probe Updates, SMART Data Rapped “Sloppy”
  August 12, 2013

• BUSINESS AZ’s Exenatide Promotion to Break Free from Weight-Loss Image of GLP-1 Receptor Agonists
  August 9, 2013

• REGULATORY MHLW Taps 12 Experts to Serve on Diovan Study Committee; J-CLEAR’s Kuwajima, JAMS’s Sone on the List
  August 9, 2013

• REGULATORY PMDA to Make Public Adverse Reactions Reported by Patients by Year-End
  August 8, 2013

• ACADEMIA NCC Sets Sights on World’s Top Development Hub with New Exploratory Clinical Research Center
  August 7, 2013

• ORGANIZATION Kenporen Report Recommends Reference to Measures Taken in UK, France to Further Promote Use of Generics in Japan
  August 7, 2013

• ACADEMIA Draft of Hypertension Guidelines Recommends CCBs, ARBs, ACE Inhibitors, and Diuretics as First-Line Drugs, Excludes Beta Blockers
  August 6, 2013

• REGULATORY EAD Director to Personally Visit Hospitals to Urge Early Price Agreement
  August 5, 2013

• BUSINESS Apo Plus to Hire 1,000 Contract MRs by 2013-End
  August 2, 2013

• REGULATORY Distribution Reform and Perpetuation of Premium for New Drug Development Are Immediate Top-Priority Issues: EAD Director Jo
  August 2, 2013

• REGULATORY CSIMC Subcommittee Discusses Revisions of Drug Pricing Rules; Some Reps Oppose Proposed Rewards for Innovation
  August 1, 2013

• ACADEMIA Ex-Novartis Employee Manipulated Blood Pressure Data in JIKEI Study: Univ. Probe
  July 31, 2013

• BUSINESS Novartis’s Third-Party Probe Finds “No Evidence” Indicating Data Falsification by Ex-Employee; Truth behind Diovan Woe Not Yet Uncovered
  July 30, 2013

ページ

• « 先頭
• ‹ Prev
• …
• 212
• 213
• 214
• 215
• 216
• 217
• 218
• 219
• 220
• …
• Next ›
• 最終 »